MedTrace Logo

The Effects of Resveratrol Supplementation on Cognition, Cerebral Blood Flow, Microbiota and Systemic Inflammation.

NCT03448094 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2020-03-17

No results posted yet for this study

Summary

Previous research shows that a diet high in fat has harmful effects on gut health. This increases the chance of developing obesity-related diseases (such as type 2 diabetes) and disrupts cognition and mood.

Research has suggested that gut health can be improved by taking certain supplements, including resveratrol (a polyphenol found primarily in red grape skins). Resveratrol has also been shown to improve brain blood flow and possibly brain function - however, there is limited research studying this.

This study will investigate the effects of 12 weeks daily consumption of resveratrol on cognitive function, cerebral blood flow, gut microbiota and systemic inflammation in overweight and obese healthy adults.

Conditions

  • Cognitive Function and Mood
  • Cerebral Blood Flow
  • Systemic Inflammation
  • Gut Microbiota
  • Overweight and Obesity

Interventions

DIETARY_SUPPLEMENT

Resveratrol

Participants will consume one of the treatment types daily for a period of three months.

DIETARY_SUPPLEMENT

Placebo

Participants will consume one of the treatment types daily for a period of three months.

Sponsors & Collaborators

  • Evolva SA

    collaborator INDUSTRY

  • Northumbria University

    lead OTHER

Principal Investigators

  • Emma Wightman, Dr · Northumbria University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-02-06
Primary Completion
2019-07-13
Completion
2019-07-13

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03448094 on ClinicalTrials.gov